We are currently planning a study with a larger sample of first-episode, drug-naive patients with schizophrenia, controlling these confounding factors, which will yield more accurate results of the relationship between serum IGF-1 levels, and clinical symptomatology in schizophrenia without drug-related influences. Here, IGF1 is linked to schizophrenia.